PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28125064-0	2017	Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility Changes.	oxophenylarsine	0-18	PML nuclear body scaffold	Homo sapiens	61-64	
28125064-3	2017	In the present study, we for the first time establish whether organic arsenic species phenylarsine oxide (PAO) could induce the mutant PML-IV (A216V) protein solubility changes and degradation.	oxophenylarsine	86-104	PML nuclear body scaffold	Homo sapiens	135-138	
28125064-3	2017	In the present study, we for the first time establish whether organic arsenic species phenylarsine oxide (PAO) could induce the mutant PML-IV (A216V) protein solubility changes and degradation.	oxophenylarsine	106-109	PML nuclear body scaffold	Homo sapiens	135-138	
28125064-4	2017	Here, three different PML protein variants (i.e., PML-IV, PML-V and mutant PML-A216V) were overexpressed in HEK293T cells and then exposed to PAO in time- and dose-dependent manners.	oxophenylarsine	142-145	PML nuclear body scaffold	Homo sapiens	22-25	
28125064-5	2017	Interestingly, PAO is found to have potential effect on induction of mutant PML-IV (A216V) protein solubility changes and degradation, but no appreciable effects were found following exposure to high concentrations of iAsIII, dimethylarsinous acid (DMAIII) and adriamycin (doxorubicin), even though they cause cell death.	oxophenylarsine	15-18	PML nuclear body scaffold	Homo sapiens	76-79	
28125064-6	2017	Our current data strongly indicate that PAO has good effects on the mutant PML protein solubility changes, and it may be helpful for improving the therapeutic strategies for arsenic-resistant APL treatments in the near future.	oxophenylarsine	40-43	PML nuclear body scaffold	Homo sapiens	75-78